These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2886098)

  • 21. [Electron-microscopic study of typical lymphocytes and atypical cells of peripheral blood during the treatment of patients with schizophrenia].
    Bonartsev PD; Brusov OS; Morozova MA; Tsutsul'kovskaia MIa
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):54-8. PubMed ID: 19817008
    [No Abstract]   [Full Text] [Related]  

  • 22. Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27.
    Meltzer HY
    Psychopharmacology (Berl); 2002 Aug; 163(1):1-3. PubMed ID: 12185394
    [No Abstract]   [Full Text] [Related]  

  • 23. Theophylline-sensitive T-lymphocyte subpopulation in schizophrenic patients.
    Bessler H; Eviatar J; Meshulam M; Tyano S; Djaldetti M; Sirota P
    Biol Psychiatry; 1987 Aug; 22(8):1025-8. PubMed ID: 3496920
    [No Abstract]   [Full Text] [Related]  

  • 24. Schizophrenia and the immune system: pathophysiology, prevention, and treatment.
    Richard MD; Brahm NC
    Am J Health Syst Pharm; 2012 May; 69(9):757-66. PubMed ID: 22517021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications.
    Kahn JP; Puertollano MA; Schane MD; Klein DF
    Am J Psychiatry; 1988 Jun; 145(6):742-4. PubMed ID: 2897166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schizophrenia drug says goodbye to dopamine.
    Weinberger DR
    Nat Med; 2007 Sep; 13(9):1018-9. PubMed ID: 17828217
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dynamics of the changes in the indicators of the T-system of immunity in patients with newly diagnosed paroxysmal progressive schizophrenia during its treatment].
    Rogozhnikova OA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(10):42-5. PubMed ID: 1686698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine neuronal tracts in schizophrenia: their pharmacology and in vivo glucose metabolism.
    Tamminga CA; Burrows GH; Chase TN; Alphs LD; Thaker GK
    Ann N Y Acad Sci; 1988; 537():443-50. PubMed ID: 2904785
    [No Abstract]   [Full Text] [Related]  

  • 29. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiology of schizophrenia - causal role for dopamine or noradrenaline?
    Iversen LL; Reynolds GP; Snyder SH
    Nature; 1983 Oct 13-19; 305(5935):577-8. PubMed ID: 6137773
    [No Abstract]   [Full Text] [Related]  

  • 31. Paroxysmal episodes of rapid blinking during hallucinatory activity in a schizophrenic patient: a possible mechanism involving pineal-mediated 'fine tuning' of dopaminergic functions.
    Sandyk R
    Int J Neurosci; 1990 Mar; 51(1-2):95-7. PubMed ID: 1979966
    [No Abstract]   [Full Text] [Related]  

  • 32. Schizophrenia.
    Freedman R
    N Engl J Med; 2003 Oct; 349(18):1738-49. PubMed ID: 14585943
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
    Widschwendter CG; Fleischhacker WW
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible mechanisms of neurodegeneration in schizophrenia.
    Pérez-Neri I; Ramírez-Bermúdez J; Montes S; Ríos C
    Neurochem Res; 2006 Oct; 31(10):1279-94. PubMed ID: 17006758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 36. [Proliferative response of schizophrenic patient's peripheral blood lymphocytes].
    Fetisova TK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(6):867-71. PubMed ID: 307889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased T cell response to mitogen and increased anti-cytoplasmic antibody in drug-free schizophrenic patients.
    Matloubi H; Vodjgani M; Nasehi AA; Niknam MH; Kazemnejad A; Salehi E; Aboufazeli T; Gheflati Z
    Iran J Immunol; 2007 Mar; 4(1):32-7. PubMed ID: 17652841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schizophrenic deficits: neuroleptics and the prefrontal cortex.
    Jobe TH; Harrow M; Martin EM; Whitfield HJ; Sands JR
    Schizophr Bull; 1994; 20(3):413-6; discussion 417-21. PubMed ID: 7973463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 40. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication.
    da Silva Alves F; Figee M; van Amelsvoort T; Veltman D; de Haan L
    Psychopharmacol Bull; 2008; 41(1):121-32. PubMed ID: 18362875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.